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Abstract
The standard of care for treatment of individuals chronically infected with hepatitis C virus is
pegylated interferon in combination with ribavirin. Efficacy is closely related to viral genotype. This
review outlines potential therapeutic strategies for treatment failures and discusses some of the
newer agents currently in development.
Introduction and context
Hepatitis C virus (HCV) affects over 170 million people
worldwide [1]. Infection itself is often asymptomatic but
long-term can lead to the development of cirrhosis and
hepatocellular carcinoma [2]. Since the molecular clon-
ing of HCV in 1989, significant research into potential
treatments for chronic HCV infection has been carried
out [3]. The current standard of care is therapy with
pegylated interferon (PEG-IFNa2a or PEG-IFNa2b) in
combination with ribavirin for between 24 and 48
weeks. In genotype 2 and 3 infections, a sustained
virological response (SVR), effectively a cure, can be
achieved in 76-82% of individuals [4]. The SVR rates in
the other genotypes are less favourable, especially the
common genotype 1 infection in which SVR rates are less
than 42-46% [5]. The question then arises of how to treat
those patients who do not achieve an SVR despite full
compliance with therapy. Potential strategies include
dose optimisation, extended duration, additional treat-
ments, and specifically targeted antiviral therapies for
HCV (STAT-C).
Recent advances
Current work suggests that retreatment of individuals
who have failed prior therapy may be beneficial in
specific subgroups. A number of studies have shown
that individuals who are relapsed responders (RRs) to
IFN and ribavirin as opposed to non-responders (NRs)
are more likely to respond to retreatment regimens, as
are those who have received prior standard IFN rather
than PEG-IFN [6]. In these studies, the SVR rates for RRs
treated with standard IFN and ribavirin were 42-45% as
opposed to 8-17% for NRs and, in the EPIC (Efficacy of
PEG-IFN in Chronic Hepatitis C) study, 36 versus 4%
for RRs and NRs, respectively, when treated with PEG-
IFN and ribavirin. Studies that have made combined
analyses on individuals treated with IFN monotherapy
or combination therapy have shown a pronounced
effect of genotype on outcome, with SVR rates of
57-60% for genotype 2/3 as compared with 14-17% for
genotype 1[7,8]. Higherdoses of ribavirin andIFN have
been tested and look most promising for difficult-to-
treat groups [9]. Weight-based dosing of ribavirin is
important in individuals with genotype 1 infection
treated with either PEG-IFNa2a or PEG-IFNa2b
[10,11]. Increasing the dose of ribavirin from 13.3 to
15.2 mg/kg per day (maximum dose of 1,600 mg
ribavirin/day) can also improve SVR rates [12].
Prolonging the duration of therapy from 48 to 72
weeks may be beneficial in patients who are slow-
responders (that is, remain PCR (polymerase chain
reaction) positive at week 4) [13]. Initial data from the
REPEAT (Retreatment with Pegasys in Patients Not
Responding to Peg-Intron Therapy) study suggested
that induction with high-dose PEG-IFNa2a (360 mg)
may be beneficial in prior NRs, but it now appears that
this enhanced benefit is more likely to be related to
extending the duration of therapy [14]. Disappoint-
ingly, a trial of consensus IFN and ribavirin in PEG-IFN
and ribavirin NRs gave SVR rates of only 6.9%
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to-treat analysis [15].
STAT-C agents, given in combination with PEG-IFN and
ribavirin, offer the greatest promise in the retreatment
of prior NRs or relapsers to current optimal treatment
regimens. However, viral resistance is common when
they are given as monotherapy, hence the necessity of
combination treatment. Two drugs, Telaprevir and
Boceprevir, both NS3-NS4A protease inhibitors, have
entered phase III testing. In phase II studies performed
in combination regimens with PEG-IFN and ribavirin,
Telaprevir achieved SVR rates of 61 and 67% [results
from the Phase 2 Study of VX-950, Pegasys, and Copegus
in Hepatitis C (PROVE)] and Boceprevir achieved an SVR
rate of 57% [results from SPRINT (Serine Protease
Inhibitor Therapy)] in IFN-naïve patients [16-18].
These agents induce a rapid decrease in HCV RNA,
which in current PEG-IFN-based regimens is associated
with SVR. PROVE 3 is currently studying Telaprevir in
previously treated individuals, it also shows greater
efficacy at the end of treatment in the relapsers to prior
treatment as opposed to NRs [19]. Of note is that these
agents can generate significant side effects, including
fatigue, anaemia, and rashes (Telaprevir). Further studies
of nucleoside polymerase inhibitors and non-nucleoside
polymerase inhibitors are under way [20-23]. Whilst the
emerging data on these new agents are exciting, viral
resistance to them has been described as early as day 8.
This has highlighted the need to avoid monotherapy and
combine them either with drugs with nonoverlapping
resistance profiles or with PEG-IFN and ribavirin [24,25].
Maintenance therapy
The concept of suppressing or halting disease progres-
sion using low-dose maintenance PEG-IFN has been
evaluated in three long-term trials: CO-PILOT (Colchi-
cine versus PegIntron Long-Term), EPIC, and HALT-C
(Hepatitis C Antiviral Long-term Treatment against
Cirrhosis). Results from the HALT-C trial were published
recently [26]. The rates of clinical outcomes and
histological progression were, in general, similar
between treated and untreated control groups, and
therefore this strategy does not represent a viable
treatment option for the majority of virologic NRs to
current therapy.
Implications for clinical practice
Current studies are beginning to report successful
retreatment with PEG-IFN and ribavirin in specific
subgroups of individuals. Individuals who are RRs may
benefit from retreatment with optimised dosages and
durations of PEG-IFN and ribavirin. The key to successful
treatment is to ensure adherence to the regimen, which
can be achieved with supportive nursing care. Induction
with PEG-IFN or use of higher and weight-based dosing
regimens of ribavirin may require additional haemato-
logical support with granulocyte-macrophage colony-
stimulating factor and erythropoietin.However, true NRs
are unlikely to gain benefit from a further course of
PEG-IFN and ribavirin.
STAT-C agents in combination with PEG-IFN and
ribavirin should become the mainstay of treatment for
this group of individuals. However, the optimal dosage
schedules for using them have yet to be determined. At
present, Telaprevir and Boceprevir represent the most
likely therapies to emerge on the market in the near
future. Until then, inclusion in trial protocols may
represent the best option for these individuals, with the
caveat that there is a theoretical risk of selecting for
resistant viral variants if these patients cannot be made
to be rapid responders.
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